Amgen Announces Repatha® Preferred Position On CVS Health Commercial Formularies
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Amgen (AMGN) Announces Addition of Repatha to CVS Health (CVS) Formulary
November 23, 2015 8:11 AM ESTAmgen (NASDAQ: AMGN) announced that CVS Health (NYSE: CVS) will provide preferred access to Repatha® (evolocumab) through its CVS/caremark commercial formularies.
"Ensuring access to Repatha for appropriate patients is among Amgen's highest priorities, and we are delighted that CVS Health has granted Repatha a preferred position on their commercial formularies," said Anthony C. Hooper, executive vice president of Global Commercial Operations at Amgen. "Value-based partnerships are a key area of focus for Amgen, and Repatha gave us a great opportunity to offer value-based contracts that... More
